Clinical Trial Update: Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for an anti-CD22 CAR-T cell therapy targeting leukemia and lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Snippet

Sponsor: Affiliated Hospital to Academy of Military Medical Sciences | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN